Background: Gene fusion events resulting from chromosomal rearrangements play an important role in initiation of lung adenocarcinoma. The recent association of four oncogenic driver genes, ALK, ROS1, RET, and NTRK1, as lung tumor predictive biomarkers has increased the need for development of up-to-date technologies for detection of these biomarkers in limited amounts of material. Methods: We describe here a multi-institutional study using the Ion AmpliSeq™ RNA Fusion Lung Cancer Research Panel to interrogate previously characterized lung tumor samples. Results: Reproducibility between laboratories using diluted fusion-positive cell lines was 100%. A cohort of lung clinical research samples from different origins (tissue biopsies, tissue re...
Oncogenic rearrangements leading to targetable gene fusions are well-established cancer driver event...
ALK, ROS1 and RET gene fusions are important predictive biomarkers for tyrosine kinase inhibitors in...
International audienceDetection of anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), an...
Background: Gene fusion events resulting from chromosomal rearrangements play an important role in i...
Gene fusion events resulting from chromosomal rearrangements play an important role in initiation of...
IntroductionROS1 and RET gene fusions were recently discovered in non–small-cell lung cancer (NSCLC)...
BACKGROUND: Anaplastic lymphoma receptor tyrosine kinase (ALK), ROS proto-oncogene 1, receptor tyros...
Oncogenic rearrangements leading to targetable gene fusions are well-established cancer driver event...
OBJECTIVES: There is an increasing number of driver fusions in NSCLC which are amenable to targeted ...
AbstractWhether Cell block (CB) samples are applicable to detect anaplastic lymphoma kinase (ALK), c...
Approximately 7% of non-small cell lung carcinomas (NSCLCs) harbor oncogenic fusions involving ALK, ...
AbstractIntroductionFusions of the anaplastic lymphoma receptor tyrosine kinase gene (ALK), ret prot...
Introduction: Gene fusions are frequent chromosomal aberrations in solid tumors. In Lung cancer (LC)...
Targeted therapy in lung cancer requires the assessment of multiple oncogenic driver alterations, in...
Aim: ALK, ROS1, NTRK and RET gene fusions and MET exon 14 skipping alterations represent novel ...
Oncogenic rearrangements leading to targetable gene fusions are well-established cancer driver event...
ALK, ROS1 and RET gene fusions are important predictive biomarkers for tyrosine kinase inhibitors in...
International audienceDetection of anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), an...
Background: Gene fusion events resulting from chromosomal rearrangements play an important role in i...
Gene fusion events resulting from chromosomal rearrangements play an important role in initiation of...
IntroductionROS1 and RET gene fusions were recently discovered in non–small-cell lung cancer (NSCLC)...
BACKGROUND: Anaplastic lymphoma receptor tyrosine kinase (ALK), ROS proto-oncogene 1, receptor tyros...
Oncogenic rearrangements leading to targetable gene fusions are well-established cancer driver event...
OBJECTIVES: There is an increasing number of driver fusions in NSCLC which are amenable to targeted ...
AbstractWhether Cell block (CB) samples are applicable to detect anaplastic lymphoma kinase (ALK), c...
Approximately 7% of non-small cell lung carcinomas (NSCLCs) harbor oncogenic fusions involving ALK, ...
AbstractIntroductionFusions of the anaplastic lymphoma receptor tyrosine kinase gene (ALK), ret prot...
Introduction: Gene fusions are frequent chromosomal aberrations in solid tumors. In Lung cancer (LC)...
Targeted therapy in lung cancer requires the assessment of multiple oncogenic driver alterations, in...
Aim: ALK, ROS1, NTRK and RET gene fusions and MET exon 14 skipping alterations represent novel ...
Oncogenic rearrangements leading to targetable gene fusions are well-established cancer driver event...
ALK, ROS1 and RET gene fusions are important predictive biomarkers for tyrosine kinase inhibitors in...
International audienceDetection of anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), an...